ore evidence on safety given safety issues observed in its inhibitors trials. ■ Expert feedback suggests Shire will emerge as dominant in HAE with Lanadelumab (launch expected in 2H18). • Shares are far too cheap at just 8x 19E PE and 9x EV/EBITDA. Shire is the cheapest stock in our coverage after '17 und